Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TheraBionic P1 + Fruquintinib in Refractory mCRC
NCT07130903Phase 2Recruiting
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Overall Survival at 5 years. Started Sep 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07130903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07130903.